Team_ SDS Zellenblick_2 Wissenschaftlerin Vail
HomeWelcome HomeDiscovery
HomeDevelopment HomeManufacturing

  1. Scil Proteins Obtains EMA Approval for Commercial Production of Reteplase

    2012-10-22

    Scil Proteins Production GmbH announced today that the European Medicines Agency (EMA) has approved Scil Proteins’ Halle facilities for manufacturing of Reteplase, marketed by Actavis as Rapilysin®.

Upcoming Conferences
  1. 2013-11-04 Bio-Europe 2013, Vienna